Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Insulins | Research

Triglyceride-glucose index in the prediction of clinical outcomes after successful recanalization for coronary chronic total occlusions

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

Triglyceride-glucose index (TyG) has been widely used to predict cardiovascular outcomes. However, it remains unclear whether TyG holds prognostic significance for patients with coronary chronic total occlusions (CTO). Thus, our study aimed to evaluate the predictive accuracy and prognostic value of TyG in individuals who underwent successful percutaneous coronary intervention (PCI) for CTO.

Methods

A total of 331 consecutive patients with ≥ 1 successful CTO-PCI were included. The baseline and angiographic data were acquired. The duration of follow-up ranged from 32 to 79 months, with a median of 44 months and an interquartile range of 39 to 67 months. The primary outcome measured was the occurrence of major adverse cardiac and cerebrovascular events (MACCE), including mortality, target vessel revascularization, recurrent myocardial infarction, and stroke.

Results

After controlling for confounders, multivariate Cox regression analysis revealed that TyG remained statistically significant, regardless of being a continuous or categorical variable. In the partially adjusted regression model, the Hazard ratio (95%CI) for MACCE was 2.54 (1.12–5.79) in tertile 3 and 1.61 (1.22–2.12) per SD increase in the TyG.Kaplan-Meier survival analysis demonstrated significant differences in MACCE-free survival rates across tertiles of the TyG, as indicated by the log-rank test (p = 0.001). ROC analysis was conducted to evaluate the predictive ability of TyG for MACCE, resulting in an AUC of 0.677.

Conclusion

The TyG index demonstrates independent predictive capabilities for MACCE in patients who have undergone successful CTO-PCI. These findings suggest that TyG holds the potential as a valuable tool in risk stratification and the identification of patients who may benefit from early intervention in the management of CTO.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012;59(11):991–7.PubMedCrossRef Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012;59(11):991–7.PubMedCrossRef
2.
go back to reference Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, et al. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015;36(45):3189–98.PubMedCrossRef Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, et al. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015;36(45):3189–98.PubMedCrossRef
3.
go back to reference Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484–93.PubMedCrossRef Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484–93.PubMedCrossRef
4.
go back to reference Zhao S, Chen Y, Wang Q, Zhu B, Wei Z, Wang Z, et al. Benefits of successful percutaneous coronary intervention in chronic total occlusion patients with Diabetes. Cardiovasc Diabetol. 2022;21(1):271.PubMedPubMedCentralCrossRef Zhao S, Chen Y, Wang Q, Zhu B, Wei Z, Wang Z, et al. Benefits of successful percutaneous coronary intervention in chronic total occlusion patients with Diabetes. Cardiovasc Diabetol. 2022;21(1):271.PubMedPubMedCentralCrossRef
5.
go back to reference Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial evaluating percutaneous coronary intervention for the Treatment of Chronic Total Occlusion. Circulation. 2019;139(14):1674–83.PubMedCrossRef Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial evaluating percutaneous coronary intervention for the Treatment of Chronic Total Occlusion. Circulation. 2019;139(14):1674–83.PubMedCrossRef
6.
go back to reference van Veelen A, Elias J, van Dongen IM, Hoebers LPC, Claessen B, Henriques JPS. Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a systematic review and meta-analysis of randomised trials. Neth Heart J. 2021;29(1):30–41.PubMedCrossRef van Veelen A, Elias J, van Dongen IM, Hoebers LPC, Claessen B, Henriques JPS. Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a systematic review and meta-analysis of randomised trials. Neth Heart J. 2021;29(1):30–41.PubMedCrossRef
7.
go back to reference Beverly JK, Budoff MJ, Atherosclerosis. Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes. 2020;12(2):102–4.PubMedCrossRef Beverly JK, Budoff MJ, Atherosclerosis. Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes. 2020;12(2):102–4.PubMedCrossRef
9.
go back to reference Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRef Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRef
10.
go back to reference Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides x glucose versus triglyceride/high-density lipoprotein cholesterol. Metabolism. 2011;60(12):1673–6.PubMedCrossRef Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides x glucose versus triglyceride/high-density lipoprotein cholesterol. Metabolism. 2011;60(12):1673–6.PubMedCrossRef
11.
go back to reference Son DH, Lee HS, Lee YJ, Lee JH, Han JH. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32(3):596–604.PubMedCrossRef Son DH, Lee HS, Lee YJ, Lee JH, Han JH. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022;32(3):596–604.PubMedCrossRef
12.
go back to reference Wang S, Shi J, Peng Y, Fang Q, Mu Q, Gu W, et al. Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 Diabetes: a real-world single-centre study. Cardiovasc Diabetol. 2021;20(1):82.PubMedPubMedCentralCrossRef Wang S, Shi J, Peng Y, Fang Q, Mu Q, Gu W, et al. Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 Diabetes: a real-world single-centre study. Cardiovasc Diabetol. 2021;20(1):82.PubMedPubMedCentralCrossRef
13.
go back to reference Li H, Zuo Y, Qian F, Chen S, Tian X, Wang P, et al. Triglyceride-glucose index variability and incident Cardiovascular Disease: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):105.PubMedPubMedCentralCrossRef Li H, Zuo Y, Qian F, Chen S, Tian X, Wang P, et al. Triglyceride-glucose index variability and incident Cardiovascular Disease: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):105.PubMedPubMedCentralCrossRef
14.
go back to reference Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in Cardiovascular Diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.PubMedPubMedCentralCrossRef Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in Cardiovascular Diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.PubMedPubMedCentralCrossRef
15.
go back to reference Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with Diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.PubMedPubMedCentralCrossRef Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with Diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.PubMedPubMedCentralCrossRef
16.
go back to reference Jiao Y, Su Y, Shen J, Hou X, Li Y, Wang J, et al. Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study. Cardiovasc Diabetol. 2022;21(1):3.PubMedPubMedCentralCrossRef Jiao Y, Su Y, Shen J, Hou X, Li Y, Wang J, et al. Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study. Cardiovasc Diabetol. 2022;21(1):3.PubMedPubMedCentralCrossRef
17.
go back to reference Luo E, Wang D, Yan G, Qiao Y, Liu B, Hou J, et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation Myocardial Infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18(1):150.PubMedPubMedCentralCrossRef Luo E, Wang D, Yan G, Qiao Y, Liu B, Hou J, et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation Myocardial Infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18(1):150.PubMedPubMedCentralCrossRef
18.
go back to reference Di Mario C, Mashayekhi KA, Garbo R, Pyxaras SA, Ciardetti N, Werner GS. Recanalisation of coronary chronic total occlusions. EuroIntervention. 2022;18(7):535–61.PubMedCrossRef Di Mario C, Mashayekhi KA, Garbo R, Pyxaras SA, Ciardetti N, Werner GS. Recanalisation of coronary chronic total occlusions. EuroIntervention. 2022;18(7):535–61.PubMedCrossRef
19.
go back to reference Cohen M, Sherman W, Rentrop KP. Determinants of collateral filling observed during sudden controlled coronary artery occlusion in human subjects. J Am Coll Cardiol. 1989;13(2):297–303.PubMedCrossRef Cohen M, Sherman W, Rentrop KP. Determinants of collateral filling observed during sudden controlled coronary artery occlusion in human subjects. J Am Coll Cardiol. 1989;13(2):297–303.PubMedCrossRef
20.
go back to reference American Diabetes A. 2. Classification and diagnosis of Diabetes: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14–S31.CrossRef American Diabetes A. 2. Classification and diagnosis of Diabetes: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14–S31.CrossRef
21.
go back to reference Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic Cardiovascular Disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic Cardiovascular Disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef
22.
go back to reference Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial Hypertension. Eur Heart J. 2018;39(33):3021–104.PubMedCrossRef Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial Hypertension. Eur Heart J. 2018;39(33):3021–104.PubMedCrossRef
23.
go back to reference Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.PubMedCrossRef Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.PubMedCrossRef
24.
go back to reference Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of Myocardial Infarction. J Am Coll Cardiol. 2012;60(16):1581–98.PubMedCrossRef Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of Myocardial Infarction. J Am Coll Cardiol. 2012;60(16):1581–98.PubMedCrossRef
25.
go back to reference Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.PubMedCrossRef Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.PubMedCrossRef
26.
go back to reference Rangaswami J, Soman S, McCullough PA. Key updates in Cardio-Nephrology from 2018: springboard to a bright future. Rev Cardiovasc Med. 2018;19(4):113–6.PubMed Rangaswami J, Soman S, McCullough PA. Key updates in Cardio-Nephrology from 2018: springboard to a bright future. Rev Cardiovasc Med. 2018;19(4):113–6.PubMed
27.
go back to reference Wang P, Yuan D, Jia S, Zhu P, Zhang C, Liu Y, et al. 5-Year clinical outcomes of successful recanalisation for coronary chronic total occlusions in patients with or without type 2 Diabetes Mellitus. Front Cardiovasc Med. 2021;8:691641.PubMedPubMedCentralCrossRef Wang P, Yuan D, Jia S, Zhu P, Zhang C, Liu Y, et al. 5-Year clinical outcomes of successful recanalisation for coronary chronic total occlusions in patients with or without type 2 Diabetes Mellitus. Front Cardiovasc Med. 2021;8:691641.PubMedPubMedCentralCrossRef
28.
29.
go back to reference Lambie M, Bonomini M, Davies SJ, Accili D, Arduini A, Zammit V. Insulin resistance in Cardiovascular Disease, uremia, and peritoneal dialysis. Trends Endocrinol Metab. 2021;32(9):721–30.PubMedPubMedCentralCrossRef Lambie M, Bonomini M, Davies SJ, Accili D, Arduini A, Zammit V. Insulin resistance in Cardiovascular Disease, uremia, and peritoneal dialysis. Trends Endocrinol Metab. 2021;32(9):721–30.PubMedPubMedCentralCrossRef
30.
31.
go back to reference Luo JW, Duan WH, Yu YQ, Song L, Shi DZ. Prognostic significance of triglyceride-glucose index for adverse Cardiovascular events in patients with coronary artery Disease: a systematic review and Meta-analysis. Front Cardiovasc Med. 2021;8:774781.PubMedPubMedCentralCrossRef Luo JW, Duan WH, Yu YQ, Song L, Shi DZ. Prognostic significance of triglyceride-glucose index for adverse Cardiovascular events in patients with coronary artery Disease: a systematic review and Meta-analysis. Front Cardiovasc Med. 2021;8:774781.PubMedPubMedCentralCrossRef
32.
go back to reference Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery Disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142.PubMedPubMedCentralCrossRef Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery Disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142.PubMedPubMedCentralCrossRef
33.
go back to reference Hu C, Zhang J, Liu J, Liu Y, Gao A, Zhu Y, et al. Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China. Cardiovasc Diabetol. 2020;19(1):116.PubMedPubMedCentralCrossRef Hu C, Zhang J, Liu J, Liu Y, Gao A, Zhu Y, et al. Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China. Cardiovasc Diabetol. 2020;19(1):116.PubMedPubMedCentralCrossRef
34.
go back to reference Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, et al. Triglyceride-glucose index as a surrogate marker of insulin resistance for Predicting Cardiovascular outcomes in nondiabetic patients with Non-ST-Segment elevation Acute Coronary Syndrome undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2021;28(11):1175–94.PubMedCrossRef Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, et al. Triglyceride-glucose index as a surrogate marker of insulin resistance for Predicting Cardiovascular outcomes in nondiabetic patients with Non-ST-Segment elevation Acute Coronary Syndrome undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2021;28(11):1175–94.PubMedCrossRef
35.
go back to reference Zhu Y, Liu K, Chen M, Liu Y, Gao A, Hu C, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20(1):137.PubMedPubMedCentralCrossRef Zhu Y, Liu K, Chen M, Liu Y, Gao A, Hu C, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20(1):137.PubMedPubMedCentralCrossRef
36.
go back to reference Li Y, He S, Wu Z, Li W, Jian W, Cheng Z, et al. The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion. Cardiovasc Diabetol. 2022;21(1):149.PubMedPubMedCentralCrossRef Li Y, He S, Wu Z, Li W, Jian W, Cheng Z, et al. The predictive value of the triglyceride-glucose index for cardiovascular events in patients with coronary chronic total occlusion. Cardiovasc Diabetol. 2022;21(1):149.PubMedPubMedCentralCrossRef
37.
go back to reference Song Y, Cui K, Yang M, Song C, Yin D, Dong Q, et al. High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study. Cardiovasc Diabetol. 2023;22(1):180.PubMedPubMedCentralCrossRef Song Y, Cui K, Yang M, Song C, Yin D, Dong Q, et al. High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study. Cardiovasc Diabetol. 2023;22(1):180.PubMedPubMedCentralCrossRef
38.
go back to reference Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of Cardiovascular Disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentralCrossRef Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of Cardiovascular Disease. Cardiovasc Diabetol. 2018;17(1):122.PubMedPubMedCentralCrossRef
39.
go back to reference Markus MRP, Rospleszcz S, Ittermann T, Baumeister SE, Schipf S, Siewert-Markus U, et al. Glucose and insulin levels are associated with arterial stiffness and concentric remodeling of the heart. Cardiovasc Diabetol. 2019;18(1):145.PubMedPubMedCentralCrossRef Markus MRP, Rospleszcz S, Ittermann T, Baumeister SE, Schipf S, Siewert-Markus U, et al. Glucose and insulin levels are associated with arterial stiffness and concentric remodeling of the heart. Cardiovasc Diabetol. 2019;18(1):145.PubMedPubMedCentralCrossRef
40.
go back to reference da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in Hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–82.PubMedCrossRef da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in Hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671–82.PubMedCrossRef
41.
go back to reference Won KB, Park EJ, Han D, Lee JH, Choi SY, Chun EJ, et al. Triglyceride glucose index is an Independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol. 2020;19(1):34.PubMedPubMedCentralCrossRef Won KB, Park EJ, Han D, Lee JH, Choi SY, Chun EJ, et al. Triglyceride glucose index is an Independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol. 2020;19(1):34.PubMedPubMedCentralCrossRef
42.
go back to reference Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride-glucose index and risk of Cardiovascular Diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124.PubMedPubMedCentralCrossRef Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride-glucose index and risk of Cardiovascular Diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124.PubMedPubMedCentralCrossRef
43.
go back to reference Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic Cardiovascular Disease and Heart Failure: determinants of risk and outcomes in patients with Diabetes. Prog Cardiovasc Dis. 2019;62(4):306–14.PubMedCrossRef Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic Cardiovascular Disease and Heart Failure: determinants of risk and outcomes in patients with Diabetes. Prog Cardiovasc Dis. 2019;62(4):306–14.PubMedCrossRef
44.
go back to reference Mancusi C, Izzo R, di Gioia G, Losi MA, Barbato E, Morisco C. Insulin resistance the Hinge between Hypertension and Type 2 Diabetes. High Blood Press Cardiovasc Prev. 2020;27(6):515–26.PubMedPubMedCentralCrossRef Mancusi C, Izzo R, di Gioia G, Losi MA, Barbato E, Morisco C. Insulin resistance the Hinge between Hypertension and Type 2 Diabetes. High Blood Press Cardiovasc Prev. 2020;27(6):515–26.PubMedPubMedCentralCrossRef
45.
go back to reference Jia G, Sowers JR. Hypertension in Diabetes: an update of Basic mechanisms and Clinical Disease. Hypertension. 2021;78(5):1197–205.PubMedCrossRef Jia G, Sowers JR. Hypertension in Diabetes: an update of Basic mechanisms and Clinical Disease. Hypertension. 2021;78(5):1197–205.PubMedCrossRef
46.
go back to reference Stalikas N, Papazoglou AS, Karagiannidis E, Panteris E, Moysidis D, Daios S, et al. Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation Myocardial Infarction. Cardiovasc Diabetol. 2022;21(1):140.PubMedPubMedCentralCrossRef Stalikas N, Papazoglou AS, Karagiannidis E, Panteris E, Moysidis D, Daios S, et al. Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation Myocardial Infarction. Cardiovasc Diabetol. 2022;21(1):140.PubMedPubMedCentralCrossRef
47.
go back to reference Chu J, Tang J, Lai Y, Gao Y, Ye Z, Guan C, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation Myocardial Infarction. J Thorac Dis. 2020;12(11):6598–608.PubMedPubMedCentralCrossRef Chu J, Tang J, Lai Y, Gao Y, Ye Z, Guan C, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation Myocardial Infarction. J Thorac Dis. 2020;12(11):6598–608.PubMedPubMedCentralCrossRef
Metadata
Title
Triglyceride-glucose index in the prediction of clinical outcomes after successful recanalization for coronary chronic total occlusions
Publication date
01-12-2023
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-02037-6

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine